CIK 0001764013
- Large accelerated filer
Immunovant, Inc.
Sign in to watch- Ticker
- IMVT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 832771572
- Phone
- +1 917-410-3120
- Business address
- 1000 PARK FORTY PLAZA, DURHAM, NC, 27713
- Former names
- Health Sciences Acquisitions Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $895,852
- in 9 filings, $173K under 10b5-1 plans
Net −$895,852. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-24 | Levine Mark S. Chief Legal Officer | Sale | −3,963 | $28.90 | $115K | 343,156 |
| 2024-04-17 | Levine Mark S. Chief Legal Officer | Sale | −7,602 | $28.80 | $219K | 349,344 |
| 2024-04-17 | Levine Mark S. Chief Legal Officer | Sale | −2,225 | $29.94 | $67K | 347,119 |
| 2024-04-17 | Macias William L. Chief Medical Officer | Sale | −6,136 | $28.80 | $177K | 379,794 |
| 2024-04-17 | Macias William L. Chief Medical Officer | Sale | −1,796 | $29.94 | $54K | 377,998 |
| 2024-04-17 | Macias William L. Chief Medical Officer | Sale | −269 | $28.80 | $8K | 377,729 |
| 2024-04-17 | Macias William L. Chief Medical Officer | Sale | −79 | $29.94 | $2K | 377,650 |
| 2024-04-17 | Barnett Eva Renee Chief Financial Officer | Sale | −9,479 | $28.80 | $273K | 362,230 |
| 2024-04-17 | Barnett Eva Renee Chief Financial Officer | Sale | −2,774 | $29.94 | $83K | 359,456 |
| 2024-04-17 | Butchko Julia G. Chief Development Officer | Sale | −7,825 | $28.80 | $225K | 453,917 |
| 2024-04-17 | Butchko Julia G. Chief Development Officer | Sale | −2,290 | $29.94 | $69K | 451,627 |
| 2024-04-17 | Salzmann Peter Chief Executive Officer | Sale | −26,365 | $28.80 | $759K | 1,060,593 |
| 2024-04-17 | Salzmann Peter Chief Executive Officer | Sale | −7,714 | $29.94 | $231K | 1,052,879 |
| 2024-04-09 | Barnett Eva Renee Chief Financial Officer | Sale | −3,689 | $31.18 | $115K | 371,709 |
| 2024-04-09 | Butchko Julia G. Chief Development Officer | Sale | −1,053 | $31.18 | $33K | 461,742 |
| 2024-04-09 | Salzmann Peter Chief Executive Officer | Sale | −4,807 | $31.18 | $150K | 1,086,958 |
| 2024-04-02 | Fromkin Andrew J. Director | Grant or award | +11,255 | 99,913 | ||
| 2024-04-02 | Fromkin Andrew J. Director | Grant or award · Stock Option (right to buy) | +4,690 | 4,690 | ||
| 2024-04-02 | Hughes Douglas J. Director | Grant or award | +11,255 | 125,010 | ||
| 2024-04-02 | Hughes Douglas J. Director | Grant or award · Stock Option (right to buy) | +4,690 | 4,690 |
Page 13 of 18 · 351 trades